NEW YORK (GenomeWeb News) – Qiagen today said that GE company Clarient will offer its therascreen KRAS RGQ PCR kit as a companion diagnostic.

Clarient will offer the test to help guide the use of Erbitux (cetuximab) for treating patients with metastatic colorectal cancer. Clarient chose the therascreen KRAS assay and Qiagen's Rotor-Gene Q molecular diagnostic platform after the US Food and Drug Administration approved the test in July, Qiagen said.